Radius Health, Inc. (RDUS)
USD 29.06
(-0.03%)
USD 29.06
(-0.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 38.31 Million USD | -83.11% |
| 2022 | 226.86 Million USD | 5.87% |
| 2021 | 214.28 Million USD | 898.89% |
| 2020 | 21.45 Million USD | 120.18% |
| 2019 | -106.32 Million USD | 45.76% |
| 2018 | -196.02 Million USD | 19.66% |
| 2017 | -243.98 Million USD | -33.9% |
| 2016 | -182.21 Million USD | -83.2% |
| 2015 | -99.46 Million USD | -65.95% |
| 2014 | -59.93 Million USD | -2.94% |
| 2013 | -58.22 Million USD | 12.34% |
| 2012 | -66.41 Million USD | -59.36% |
| 2011 | -41.67 Million USD | -88989.82% |
| 2010 | -46.78 Thousand USD | -46.23% |
| 2009 | -31.99 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | -83.11% |
| 2023 Q1 | 9.27 Million USD | 149.84% |
| 2023 Q2 | 26.37 Million USD | 184.51% |
| 2023 Q3 | 21.26 Million USD | -19.38% |
| 2023 Q4 | -23.12 Million USD | -208.73% |
| 2022 Q4 | -18.6 Million USD | -214.95% |
| 2022 Q1 | -13.06 Million USD | -18.51% |
| 2022 Q2 | -7.48 Million USD | 42.74% |
| 2022 FY | - USD | 5.87% |
| 2022 Q3 | 16.18 Million USD | 316.29% |
| 2021 Q2 | -11.72 Million USD | -5.26% |
| 2021 Q3 | -16.88 Million USD | -44.04% |
| 2021 Q4 | -11.02 Million USD | 34.68% |
| 2021 Q1 | -11.13 Million USD | -261.0% |
| 2021 FY | - USD | 898.89% |
| 2020 Q1 | -30.74 Million USD | -71.66% |
| 2020 Q3 | 1.09 Million USD | 102.98% |
| 2020 Q4 | 6.91 Million USD | 533.88% |
| 2020 FY | - USD | 120.18% |
| 2020 Q2 | -36.66 Million USD | -19.28% |
| 2019 Q1 | -36.09 Million USD | -3.63% |
| 2019 Q2 | -28.86 Million USD | 20.02% |
| 2019 Q4 | -17.9 Million USD | 23.22% |
| 2019 Q3 | -23.32 Million USD | 19.19% |
| 2019 FY | - USD | 45.76% |
| 2018 Q1 | -55.31 Million USD | 14.79% |
| 2018 FY | - USD | 19.66% |
| 2018 Q4 | -34.82 Million USD | 19.65% |
| 2018 Q3 | -43.34 Million USD | 30.68% |
| 2018 Q2 | -62.52 Million USD | -13.04% |
| 2017 FY | - USD | -33.9% |
| 2017 Q4 | -64.91 Million USD | -19.35% |
| 2017 Q3 | -54.39 Million USD | 20.01% |
| 2017 Q2 | -67.99 Million USD | -19.95% |
| 2017 Q1 | -56.68 Million USD | -7.96% |
| 2016 Q4 | -52.5 Million USD | -14.06% |
| 2016 FY | - USD | -83.2% |
| 2016 Q1 | -40.36 Million USD | -21.62% |
| 2016 Q3 | -46.03 Million USD | -6.27% |
| 2016 Q2 | -43.31 Million USD | -7.3% |
| 2015 FY | - USD | -65.95% |
| 2015 Q2 | -22.12 Million USD | -36.4% |
| 2015 Q1 | -16.22 Million USD | 5.34% |
| 2015 Q3 | -27.92 Million USD | -26.18% |
| 2015 Q4 | -33.19 Million USD | -18.87% |
| 2014 Q1 | -14.07 Million USD | -17.03% |
| 2014 FY | - USD | -2.94% |
| 2014 Q4 | -17.14 Million USD | -3.37% |
| 2014 Q3 | -16.58 Million USD | -36.57% |
| 2014 Q2 | -12.14 Million USD | 13.71% |
| 2013 Q2 | -18.85 Million USD | -148.27% |
| 2013 Q3 | -19.75 Million USD | -4.76% |
| 2013 Q4 | -12.02 Million USD | 39.13% |
| 2013 FY | - USD | 12.34% |
| 2013 Q1 | -7.59 Million USD | 62.15% |
| 2012 Q4 | -20.06 Million USD | -21.09% |
| 2012 Q1 | -12.41 Million USD | -23.58% |
| 2012 Q2 | -17.36 Million USD | -39.89% |
| 2012 Q3 | -16.57 Million USD | 4.59% |
| 2012 FY | - USD | -59.36% |
| 2011 Q4 | -10.04 Million USD | -9.7% |
| 2011 Q1 | -10.14 Thousand USD | 59.87% |
| 2011 Q2 | -17.48 Million USD | -172235.6% |
| 2011 Q3 | -9.15 Million USD | 47.61% |
| 2011 FY | - USD | -88989.82% |
| 2010 Q3 | -6038.00 USD | -4.92% |
| 2010 Q2 | -5755.00 USD | 40.74% |
| 2010 FY | - USD | -46.23% |
| 2010 Q1 | -9711.00 USD | -93.72% |
| 2010 Q4 | -25.27 Thousand USD | -318.65% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | -5013.00 USD | 20.73% |
| 2009 Q3 | -6324.00 USD | 4.51% |
| 2009 Q2 | -6623.00 USD | 52.8% |
| 2009 Q1 | -14.03 Thousand USD | 0.0% |
| 2008 Q3 | -7044.00 USD | 0.0% |
| 2008 Q4 | - USD | 100.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 87.575% |
| Embecta Corp. | 245.4 Million USD | 84.389% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 64.956% |
| Dynavax Technologies Corporation | 9.66 Million USD | -296.338% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 125.522% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 76.482% |
| PainReform Ltd. | -9.56 Million USD | 500.355% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -3141.117% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 1101.721% |
| SCYNEXIS, Inc. | 73.47 Million USD | 47.863% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 1729.512% |
| Cosmos Health Inc. | -17.06 Million USD | 324.537% |
| Journey Medical Corporation | 1.92 Million USD | -1894.274% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 1101.721% |
| Safety Shot Inc | -12.18 Million USD | 414.398% |
| Alpha Teknova, Inc. | -25.53 Million USD | 250.006% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 124.117% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 63.173% |
| Theratechnologies Inc. | -10.31 Million USD | 471.48% |
| Harrow Health, Inc. | 9.72 Million USD | -294.014% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 946.63% |
| Biofrontera Inc. | -18.45 Million USD | 307.609% |
| DURECT Corporation | -24.68 Million USD | 255.202% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 61.012% |
| Cronos Group Inc. | -72.14 Million USD | 153.098% |
| OptiNose, Inc. | -15.55 Million USD | 346.319% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 104.142% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 206.175% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -45.853% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -6.325% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 1076.709% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 5489.323% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 1291.576% |
| ProPhase Labs, Inc. | -14.82 Million USD | 358.38% |
| Phibro Animal Health Corporation | 84.6 Million USD | 54.72% |
| Procaps Group S.A. | 104.02 Million USD | 63.173% |
| Alvotech | -484.86 Million USD | 107.901% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 556.017% |
| Viatris Inc. | 3.51 Billion USD | 98.911% |
| Rockwell Medical, Inc. | -4.69 Million USD | 916.148% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 3885.573% |
| SIGA Technologies, Inc. | 84.15 Million USD | 54.479% |
| Tilray Brands, Inc. | -72.84 Million USD | 152.593% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -4617.98% |
| Shineco, Inc. | -26.55 Million USD | 244.273% |
| PetIQ, Inc. | 81.48 Million USD | 52.986% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 1158.981% |
| Incannex Healthcare Limited | -18.5 Million USD | 307.036% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 90.793% |
| Alimera Sciences, Inc. | 7.27 Million USD | -426.526% |
| Silver Spike Investment Corp. | 7.34 Million USD | -421.927% |
| Assertio Holdings, Inc. | -222.44 Million USD | 117.222% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 1059.994% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 1009.572% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 327.981% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 291.256% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 125.69% |
| Hempacco Co., Inc. | -12.77 Million USD | 399.923% |
| Talphera, Inc. | -9.84 Million USD | 489.25% |
| Alvotech | -484.86 Million USD | 107.901% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 50.569% |
| Lantheus Holdings, Inc. | 491 Million USD | 92.198% |
| Currenc Group, Inc. | -1.9 Million USD | 2115.707% |
| Kamada Ltd. | 21.53 Million USD | -77.905% |
| Indivior PLC | 66 Million USD | 41.955% |
| Evoke Pharma, Inc. | -7.29 Million USD | 625.349% |
| Flora Growth Corp. | -45.87 Million USD | 183.519% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 291.256% |
| Evolus, Inc. | -41.81 Million USD | 191.629% |
| HUTCHMED (China) Limited | 25.52 Million USD | -50.071% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 84.134% |
| Akanda Corp. | -27.73 Million USD | 238.125% |